Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Transition Therapeutics has reported results from its exploratory phase IIa clinical trial indicating that four weeks of daily treatments with its gastrin-based therapy showed sustained reductions in blood glucose levels in type II diabetic patients.
Subscribe to our email newsletter
The patients enrolled in this study were using metformin with or without thiazolidinediones. The results showed sustained reductions in blood glucose control parameters, including haemoglobinA1C (HbA1c), for six months post-treatment.
“The improvements in HbA1c correlated with changes in multiple other clinical parameters suggesting that gastrin-based therapies, and specifically E1-INT, have the potential to re-engage the body’s natural mechanism to regulate glucose,” said Dr Tony Cruz, chairman and CEO of Transition. “The immediate goal is to optimize the dosing regimen in a larger phase II study.”